OSE Immunotherapeutics SA (EPA:OSE)

Market Cap	96.41M -37.3%
Revenue (ttm)	1.78M -95.8%
Net Income	-32.52M
EPS	-1.48
Shares Out	22.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,985
Average Volume	76,530
Open	4.370
Previous Close	4.388
Day's Range	4.284 - 4.398
52-Week Range	4.222 - 7.700
Beta	0.51
RSI	35.17
Earnings Date	Mar 27, 2026

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 64
• Stock Exchange: Euronext Paris
• Ticker Symbol: OSE